quinazolines has been researched along with hmpl-013 in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (45.71) | 24.3611 |
| 2020's | 19 (54.29) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, Y; Guo, L; Li, K; Ren, H; Sai, Y; Su, W; Wang, J; Zhang, L; Zhang, W | 1 |
| Cai, H; Cui, Y; Gu, Y; Guo, M; Hong, M; Liang, J; Long, J; Ni, L; Qing, W; Ren, Y; Sai, Y; Su, W; Sun, J; Sun, Q; Yang, H; Yang, Z; Yin, F; Zhang, M; Zhang, W; Zhang, Z; Zhou, F; Zhou, J | 1 |
| Cao, J; Chen, Z; Fan, S; Li, J; Li, K; Peng, W; Su, W; Zhang, J | 1 |
| Bai, Y; Cao, J; Fan, S; Hua, Y; Li, J; Liu, T; Pan, H; Shen, L; Su, W; Wang, L; Xu, J; Xu, RH; Zhang, D | 1 |
| Chen, J; Jin, K; Liu, Y; Ou, N; Shao, F; Wang, L; Xie, L; Xu, Z; Zhang, H; Zhou, S | 1 |
| An, T; Chang, J; Chen, M; Hua, Y; Li, W; Liu, X; Liu, Z; Lu, S; Lu, Y; Shi, J; Su, W; Wang, J; Yang, JJ; Yang, L; Zhou, J; Zhou, X | 1 |
| Chen, XY; Jiang, JF; Zhong, DF | 1 |
| Bai, Y; Cao, P; Chen, D; Chen, H; Chen, ZD; Cheng, Y; Deng, Y; Fan, S; Guo, W; Hua, Y; Li, J; Li, W; Liu, T; Ma, D; Pan, H; Qin, S; Shen, L; Shu, Y; Su, W; Sun, S; Wang, H; Wang, J; Wang, S; Wu, C; Xu, J; Xu, N; Xu, RH; Yang, L; Yu, Z; Yuan, Y; Zhong, H; Zhou, J | 1 |
| Burki, TK | 1 |
| Shirley, M | 1 |
| Chen, Z; Jiang, L | 1 |
| Chen, Q; Fan, S; Jia, J; Li, K; Li, T; Liu, Y; Qian, H; Sai, Y; Su, W; Wang, W; Yu, C | 1 |
| Binglan, Z; Jing, Z; Rui, Z | 1 |
| Deng, Y; Li, X | 1 |
| Guo, J; Luo, SB; Mei, YB; Qiu, XJ; Xie, SL; Ye, LY; Zhang, Q | 1 |
| Chen, J; Lin, H; Peng, Y; Wang, J | 1 |
| Li, J; Peng, Z; Shen, L; Wang, Q; Wang, X; Zhang, Q | 1 |
| Li, Q; Xie, D; Zhang, PF | 1 |
| Bai, C; Cao, L; Chang, J; Chen, G; Chen, Y; Chen, Z; Cheng, Y; Fang, J; Gong, Y; Guan, S; He, J; Hu, C; Hu, Y; Huang, D; Huang, Y; Jie, Z; Li, W; Liang, L; Liao, W; Liu, M; Liu, X; Liu, Z; Lu, J; Lu, S; Ma, R; Ma, S; Mao, W; Pan, H; Peng, M; Qin, S; Qiu, F; Shan, L; Shi, J; Song, Y; Su, W; Sun, S; Sun, Y; Tao, M; Wang, B; Yang, J; Yang, Z; Yao, Y; Ye, F; Zhang, Y; Zheng, Z; Zhou, J | 1 |
| Cheng, Y; Du, FC; Duan, ZJ; Fang, FQ; Lei, W; Shi, KG | 1 |
| Bai, Y; Cao, P; Chen, D; Chen, H; Chen, Z; Cheng, Y; Deng, Y; Fan, S; Guo, W; Guo, X; Han, R; Li, J; Li, W; Liu, T; Ma, D; Pan, H; Qin, S; Shen, L; Shu, Y; Sun, S; Wang, H; Wang, N; Wang, S; Wu, C; Xu, J; Xu, N; Xu, R; Yang, L; Yu, Z; Yuan, Y; Zhang, B; Zhong, H; Zhou, J | 1 |
| Cai, X; Gao, J; Gu, Y; Guo, W; Sun, Y; Wang, B; Wang, Y; Wei, B; Xu, L; Xu, Q; Zhong, H | 1 |
| Hou, X; Hua, X; Huang, Y; Peng, Z; Xie, T | 1 |
| Ding, K; Ding, Y; Wang, J; Xu, D; Yuan, Y; Zhu, N | 1 |
| Guo, A; Ju, Y; Li, L; Li, W; Liu, W; Liu, X; Sang, A; Tu, Y; Zhou, Y; Zhu, M | 1 |
| Bai, Y; Cao, P; Chen, D; Chen, H; Chen, Z; Cheng, Y; Deng, Y; Guo, W; Guo, X; Han, R; Li, J; Li, W; Liu, T; Ma, D; Pan, H; Qin, S; Shu, Y; Su, W; Sun, S; Wang, H; Wang, J; Wang, N; Wang, S; Wu, C; Xu, J; Xu, N; Xu, R; Yang, L; Yu, Z; Yuan, Y; Zhang, B; Zhong, H; Zhou, J | 1 |
| Bai, Y; Chen, Y; Chen, Z; Deng, Y; Fan, S; Guo, W; Guo, X; Li, H; Li, J; Pan, H; Peng, C; Peng, M; Qin, S; Shen, L; Shu, Y; Wang, N; Xu, J; Xu, RH; Yang, L; Zhong, H | 1 |
| Chien, C; Dasari, A; Eng, C; Kania, M; Schelman, W; Sobrero, A; Tabernero, J; Yang, Z; Yao, J; Yoshino, T | 1 |
| Jiang, FE; Liu, AN; Yu, CY; Zhang, HJ | 1 |
| Meng, R; Peng, F; Wang, J; Zeng, H; Zhang, J | 1 |
| Liang, J; Liu, J; Liu, S; Lu, L; Pan, F; Shen, R; Wang, J; Xin, FZ; Yang, C; Zhang, N | 1 |
| Cao, Y; Chen, M; Li, J; Lu, M; Peng, Z; Qi, C; Shen, L; Wang, X; Wang, Z; Zhang, J; Zhang, Q | 1 |
| Feng, N; Gao, M; Jiang, Q; Tian, Q; Wu, D; Xin, X; Yang, H; Yu, T; Zhang, J; Zhang, N; Zhang, Z; Zhao, S | 1 |
| Huang, J; Li, J; Shen, L; Su, WG; Wang, ZX; Xu, RH; Zhang, DS; Zhang, Y | 1 |
| Chien, C; Gonzalez, M; Kania, M; Schelman, W; Ukrainskyj, S; Wang-Gillam, A; Yang, Z; Yeckes-Rodin, H | 1 |
7 review(s) available for quinazolines and hmpl-013
| Article | Year |
|---|---|
[Metabolic research of domestically developed small molecule tyrosine kinase inhibitors].
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Benzofurans; China; Crown Ethers; Drug Interactions; Humans; Indoles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quinazolines | 2016 |
Fruquintinib: First Global Approval.
Topics: Antineoplastic Agents; Benzofurans; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-1 | 2018 |
The clinical application of fruquintinib on colorectal cancer.
Topics: Angiogenesis Inhibitors; Animals; Benzofurans; Colorectal Neoplasms; Drug Resistance, Neoplasm; Humans; Molecular Targeted Therapy; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2019 |
A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis.
Topics: Benzofurans; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Network Meta-Analysis; Phenylurea Compounds; Pyridines; Quinazolines; Treatment Outcome | 2019 |
Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Humans; Network Meta-Analysis; Phenylurea Compounds; Pyridines; Pyrrolidines; Quinazolines; Rectal Neoplasms; Thymine; Trifluridine; Uracil | 2019 |
Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
Topics: Antineoplastic Agents; Benzofurans; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Network Meta-Analysis; Phenylurea Compounds; Progression-Free Survival; Pyridines; Pyrrolidines; Quinazolines; Randomized Controlled Trials as Topic; Thymine; Time Factors; Trifluridine; Uracil | 2020 |
Fruquintinib effectively controlled the advanced small bowel adenocarcinoma progressed after multiple lines of palliative treatment: a case report and literature review.
Topics: Adenocarcinoma; Benzofurans; Colonic Neoplasms; Humans; Intestine, Small; Male; Middle Aged; Palliative Care; Quinazolines | 2020 |
11 trial(s) available for quinazolines and hmpl-013
| Article | Year |
|---|---|
A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Asian People; Benzofurans; Drug Administration Schedule; Female; Half-Life; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Young Adult | 2016 |
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2017 |
A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [
Topics: Adult; Benzofurans; China; Healthy Volunteers; Humans; Male; Quinazolines; Vascular Endothelial Growth Factor A | 2017 |
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non‒Small-Cell Lung Cancer.
Topics: Aged; Asian People; Benzofurans; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Placebos; Progression-Free Survival; Quinazolines | 2018 |
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzofurans; China; Colorectal Neoplasms; Combined Modality Therapy; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Quinazolines; Survival Analysis; Vascular Endothelial Growth Factor A; Young Adult | 2018 |
Effects of a High-fat Meal on the Pharmacokinetics of the VEGFR Inhibitor Fruquintinib: A Randomized Phase I Study in Healthy Subjects.
Topics: Administration, Oral; Adolescent; Adult; Benzofurans; Biological Availability; Cross-Over Studies; Dietary Fats; Fasting; Food-Drug Interactions; Healthy Volunteers; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Young Adult | 2019 |
A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; Double-Blind Method; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A | 2020 |
Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial.
Topics: Benzofurans; China; Colorectal Neoplasms; Humans; Quinazolines | 2020 |
Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III trial.
Topics: Aged; Benzofurans; Colorectal Neoplasms; Double-Blind Method; ErbB Receptors; Female; Humans; Male; Middle Aged; Progression-Free Survival; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2021 |
FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzofurans; Colorectal Neoplasms; Double-Blind Method; Humans; Protein Kinase Inhibitors; Quinazolines | 2021 |
Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States.
Topics: Antineoplastic Agents; Benzofurans; Humans; Maximum Tolerated Dose; Neoplasms; Quinazolines | 2023 |
17 other study(ies) available for quinazolines and hmpl-013
| Article | Year |
|---|---|
Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics.
Topics: Angiogenesis Inhibitors; Animals; Benzofurans; Bile; Biological Availability; Caco-2 Cells; Cells, Cultured; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Interactions; Drugs, Investigational; Female; Food-Drug Interactions; Humans; Inactivation, Metabolic; Intestinal Absorption; Male; Microsomes, Liver; Models, Biological; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Receptors, Vascular Endothelial Growth Factor | 2014 |
Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzofurans; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Epithelial Cells; Female; Humans; Inhibitory Concentration 50; Mice; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Burden; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Xenograft Model Antitumor Assays | 2014 |
Fruquintinib for previously treated metastatic colorectal cancer.
Topics: Antineoplastic Agents; Benzofurans; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Humans; Male; Quinazolines; Salvage Therapy | 2018 |
Fruquintinib and its use in the treatment of metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Benzofurans; Cell Proliferation; China; Clinical Trials as Topic; Colorectal Neoplasms; Europe; Humans; Neoplasm Metastasis; Neovascularization, Pathologic; Phosphorylation; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2019 |
Validated UPLC-MS/MS method for quantification of fruquintinib in rat plasma and its application to pharmacokinetic study.
Topics: Animals; Benzofurans; Chromatography, High Pressure Liquid; Molecular Structure; Quinazolines; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry; Tissue Distribution | 2019 |
Cost-effectiveness analysis of fruquintinib as third-line treatment for patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Colorectal Neoplasms; Cost-Benefit Analysis; Female; Humans; Male; Markov Chains; Neoplasm Metastasis; Progression-Free Survival; Quality-Adjusted Life Years; Quinazolines | 2020 |
Third-line treatment for metastatic colorectal cancer: anlotinib is superior to chemotherapy and similar to fruquintinib or regorafenib.
Topics: Benzofurans; Colorectal Neoplasms; Humans; Indoles; Phenylurea Compounds; Pyridines; Quinazolines; Quinolines | 2020 |
Combination of Fruquintinib and Anti-PD-1 for the Treatment of Colorectal Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzofurans; CD8 Antigens; Cell Line, Tumor; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Disease Models, Animal; Drug Synergism; Humans; Immune Checkpoint Inhibitors; Male; Mice; Mice, Knockout; Microsatellite Instability; Programmed Cell Death 1 Receptor; Quinazolines; Receptors, Vascular Endothelial Growth Factor; T-Lymphocytes, Regulatory; Treatment Outcome; Tumor Microenvironment; Young Adult | 2020 |
Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China.
Topics: Benzofurans; China; Colorectal Neoplasms; Cost-Benefit Analysis; Humans; Neoplasm Metastasis; Quinazolines | 2020 |
Fruquintinib inhibits VEGF/VEGFR2 axis of choroidal endothelial cells and M1-type macrophages to protect against mouse laser-induced choroidal neovascularization.
Topics: Animals; Benzofurans; Cell Movement; Cell Proliferation; Choroidal Neovascularization; Disease Models, Animal; Endothelial Cells; Humans; Macrophages; Male; Mice; Mice, Transgenic; Quinazolines; Vascular Endothelial Growth Factor A | 2020 |
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESCO trial.
Topics: Aged; Benzofurans; Cancer Survivors; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Female; Humans; Male; Middle Aged; Placebos; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2021 |
Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study.
Topics: Antibodies, Monoclonal, Humanized; Benzofurans; Colorectal Neoplasms; DNA Mismatch Repair; Humans; Microsatellite Repeats; Phenylurea Compounds; Pilot Projects; Pyridines; Quinazolines; Retrospective Studies | 2021 |
Effects of Fruquintinib on the Pluripotency Maintenance and Differentiation Potential of Mouse Embryonic Stem Cells.
Topics: Animals; Benzofurans; Cell Differentiation; Mice; Mouse Embryonic Stem Cells; Pluripotent Stem Cells; Quinazolines; Signal Transduction | 2021 |
Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer.
Topics: Benzofurans; China; Colonic Neoplasms; Colorectal Neoplasms; Humans; Quinazolines; Retrospective Studies; Vascular Endothelial Growth Factor A | 2022 |
Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic Colorectal Cancer-An Observational Cohort Study in the Real World.
Topics: Benzofurans; Colonic Neoplasms; Colorectal Neoplasms; Humans; Phenylurea Compounds; Prospective Studies; Pyridines; Quinazolines; Rectal Neoplasms; Retrospective Studies | 2022 |
Combining Fruquintinib and Doxorubicin in Size-Converted Nano-Drug Carriers for Tumor Therapy.
Topics: Benzofurans; Doxorubicin; Drug Carriers; Humans; Liposomes; Nanoparticles; Neoplasms; Quinazolines; Tumor Microenvironment | 2022 |
A phase Ib/II study of fruquintinib in combination with paclitaxel as the second-line therapy for advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Paclitaxel; Quinazolines; Stomach Neoplasms | 2023 |